Cargando…

In silico multi-epitope Bunyumwera virus vaccine to target virus nucleocapsid N protein

BACKGROUND: Bunyumwera virus can cause 82% mortality in humans currently with no vaccine or drugs for treatment. We described an in silico multi-epitope vaccine targeting Bunyumwera virus nucleocapsid N-protein and predicted B and T cell epitopes for immunogenicity, allergenicity, toxicity, and cons...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelluri, Kanaka Durga Devi, Ammulu, Manne Anupama, Durga, M. Lakshmi, Sravani, Melika, Kumar, Vemuri Praveen, Poda, Sudhakar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208256/
https://www.ncbi.nlm.nih.gov/pubmed/35723807
http://dx.doi.org/10.1186/s43141-022-00355-y
_version_ 1784729703913881600
author Nelluri, Kanaka Durga Devi
Ammulu, Manne Anupama
Durga, M. Lakshmi
Sravani, Melika
Kumar, Vemuri Praveen
Poda, Sudhakar
author_facet Nelluri, Kanaka Durga Devi
Ammulu, Manne Anupama
Durga, M. Lakshmi
Sravani, Melika
Kumar, Vemuri Praveen
Poda, Sudhakar
author_sort Nelluri, Kanaka Durga Devi
collection PubMed
description BACKGROUND: Bunyumwera virus can cause 82% mortality in humans currently with no vaccine or drugs for treatment. We described an in silico multi-epitope vaccine targeting Bunyumwera virus nucleocapsid N-protein and predicted B and T cell epitopes for immunogenicity, allergenicity, toxicity, and conservancy. For creating the most potent immunological response possible, docking epitopes with HLA alleles are chosen to screen them. The 3D vaccination was docked with the Toll-like receptor-8 using molecular dynamic simulations. To ensure production efficiency, the vaccine sequence was further cloned in silico in a plasmid pIB2 vector. For efficacy and safety, results must be supported in vitro and in vivo. RESULTS: The vaccine was cloned to enable expression and translation in a plasmid vector pIB2. It was expected to be antigenic, non-allergenic, and have a high binding affinity with TLR-8 in silico cloning. This multi-epitope vaccination may stimulate both innate and adaptive immunity. CONCLUSION: The vaccine developed in this work was based on the nucleocapsid N-protein of the Bunyumwera virus and was created using a reverse vaccinology method. Further experimental validation is required to assess the vaccine’s therapeutic effectiveness and immunogenicity.
format Online
Article
Text
id pubmed-9208256
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-92082562022-06-21 In silico multi-epitope Bunyumwera virus vaccine to target virus nucleocapsid N protein Nelluri, Kanaka Durga Devi Ammulu, Manne Anupama Durga, M. Lakshmi Sravani, Melika Kumar, Vemuri Praveen Poda, Sudhakar J Genet Eng Biotechnol Research BACKGROUND: Bunyumwera virus can cause 82% mortality in humans currently with no vaccine or drugs for treatment. We described an in silico multi-epitope vaccine targeting Bunyumwera virus nucleocapsid N-protein and predicted B and T cell epitopes for immunogenicity, allergenicity, toxicity, and conservancy. For creating the most potent immunological response possible, docking epitopes with HLA alleles are chosen to screen them. The 3D vaccination was docked with the Toll-like receptor-8 using molecular dynamic simulations. To ensure production efficiency, the vaccine sequence was further cloned in silico in a plasmid pIB2 vector. For efficacy and safety, results must be supported in vitro and in vivo. RESULTS: The vaccine was cloned to enable expression and translation in a plasmid vector pIB2. It was expected to be antigenic, non-allergenic, and have a high binding affinity with TLR-8 in silico cloning. This multi-epitope vaccination may stimulate both innate and adaptive immunity. CONCLUSION: The vaccine developed in this work was based on the nucleocapsid N-protein of the Bunyumwera virus and was created using a reverse vaccinology method. Further experimental validation is required to assess the vaccine’s therapeutic effectiveness and immunogenicity. Springer Berlin Heidelberg 2022-06-20 /pmc/articles/PMC9208256/ /pubmed/35723807 http://dx.doi.org/10.1186/s43141-022-00355-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Nelluri, Kanaka Durga Devi
Ammulu, Manne Anupama
Durga, M. Lakshmi
Sravani, Melika
Kumar, Vemuri Praveen
Poda, Sudhakar
In silico multi-epitope Bunyumwera virus vaccine to target virus nucleocapsid N protein
title In silico multi-epitope Bunyumwera virus vaccine to target virus nucleocapsid N protein
title_full In silico multi-epitope Bunyumwera virus vaccine to target virus nucleocapsid N protein
title_fullStr In silico multi-epitope Bunyumwera virus vaccine to target virus nucleocapsid N protein
title_full_unstemmed In silico multi-epitope Bunyumwera virus vaccine to target virus nucleocapsid N protein
title_short In silico multi-epitope Bunyumwera virus vaccine to target virus nucleocapsid N protein
title_sort in silico multi-epitope bunyumwera virus vaccine to target virus nucleocapsid n protein
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208256/
https://www.ncbi.nlm.nih.gov/pubmed/35723807
http://dx.doi.org/10.1186/s43141-022-00355-y
work_keys_str_mv AT nellurikanakadurgadevi insilicomultiepitopebunyumweravirusvaccinetotargetvirusnucleocapsidnprotein
AT ammulumanneanupama insilicomultiepitopebunyumweravirusvaccinetotargetvirusnucleocapsidnprotein
AT durgamlakshmi insilicomultiepitopebunyumweravirusvaccinetotargetvirusnucleocapsidnprotein
AT sravanimelika insilicomultiepitopebunyumweravirusvaccinetotargetvirusnucleocapsidnprotein
AT kumarvemuripraveen insilicomultiepitopebunyumweravirusvaccinetotargetvirusnucleocapsidnprotein
AT podasudhakar insilicomultiepitopebunyumweravirusvaccinetotargetvirusnucleocapsidnprotein